Innate Pharma presented data from a preliminary analysis of the TELLOMAK Phase 2 trial demonstrating clinical activity and a favorable safety profile for lacutamab, a first-in-class anti-KIR3DL2 humanized cytotoxicity-inducing antibody, in patients with advanced Sezary syndrome, a form of T cell lymphoma. The data were presented during the 2022 ASH Annual Meeting, in New Orleans. At the time of data cut off, the Intention To Treat population included 37 post mogamulizumab patients with advanced, highly refractory Sezary syndrome, and 35 patients were Evaluable for Efficacy. The patient population was heavily pre-treated with a median of 6 prior lines of therapy. The median follow-up was 10.9 months. In the ITT population, the global objective response rate was 21.6%. ORR in the blood was 37.8%, with 21.6% achieving complete response. ORR in the skin was 35.1%. In the EES population, global objective response rate was 22.9%. ORR in the blood was 40.0% and ORR in the skin was 37.1%. Within the subgroup of patients that achieved a global response, median duration of global response was 10.8 months with median time to global response of 4 months; median time to blood response was 1.0 month and median time to skin response was 2.8 months. In line with previous observations, lacutamab demonstrated a favorable safety profile for patients with advanced Sezary syndrome in the TELLOMAK Phase 2 preliminary analysis. Grade greater than or equal to 3 Treatment-related Treatment-Emergent Adverse events were observed in 6/37 patients.
Published first on TheFly
